IRRAS Expands Intellectual Property Portfolio with Issuance of Additional Patent for IRRAflow System

Stockholm, January 12, 2022 – IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced the issuance of United States (U.S.) Patent Number 11,123,483, “Fluid Exchange Catheter System.”  This latest patent is the third US patent that provides intellectual property protection for the company’s lead product, IRRAflow, and it provides expanded coverage regarding the system’s ability to facilitate the targeted delivery of therapeutic medication into targeted areas of treatment.

The recently issued patent includes two key method claims regarding the IRRAflow system’s active fluid exchange mechanism of action.  The patent’s protection covers:

  1. The administration of at least one drug to a patient through the catheter; and
  2. The irrigation mechanism for unblocking the fluid exchange pores at the distal end of the catheter. 

The issuance of the latest patent adds to the existing intellectual property protection for the IRRAflow system and builds upon the previously issued US patents, U.S. Patent No. 8,398,581, issued on March 19, 2013, and U.S. Patent No. 9,623,177, issued on April 18, 2017.  IRRAS’ IRRAflow and Hummingbird ICP Monitoring product families now contain 12 total patents nationalized globally across 13 key countries.

“Strengthening our intellectual property portfolio with the addition of this patent further confirms the innovative technology contained with the IRRAflow system,” said Will Martin, President and Chief Executive Officer of IRRAS.  “Over the past year, global thought leaders in neurosurgery from Helsinki University Hospital and Buffalo General Medical Center centers have published cutting-edge clinical experience using IRRAflow to deliver both thrombolytic and antibiotic medication.  Moving forward, IRRAS is committed to capitalizing upon this sizable opportunity in intracranial drug delivery, and this patent is an important foundational element of our company’s long-term growth plans.”

IRRAflow, the company's initial commercial product, is a transformative medical device system that combines controlled irrigation with ongoing fluid drainage to better manage patients with intracranial bleedings.  The system's automated use of irrigation addresses challenges associated with traditional passive fluid drainage, such as catheter blockages and infection. In addition, IRRAflow's irrigating fluid helps to dilute toxic material, such as blood or bacteria, that is collected within the intracranial space and makes it easier to remove.


IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit

IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

Sten Gustafsson
Director, Investor Relations
+46 102 11 5172

The information was released for public disclosure, through the agency of the contact person above, on January 12, 2022, at 8:30 (CET).

Irras Radio Irras Academy

At IRRAS, your privacy and the protection of your personal data are important to us. To ensure GDPR compliance, this website does not store or track any personal information, including Google Analytics or form submission data.
By using the website, you acknowledge and accept our policy.